Intellectual Property India Publishes Patent Application for 'Tetrahydroquinoline Derivatives For Inhibiting Cav3.2-Usp5 Interactions' Filed by Zymedyne Therapeutics Inc.

MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517090706 A) filed by Zymedyne Therapeutics Inc., Calgary, Canada, on Sept. 23, for 'tetrahydroquinoline derivatives for inhibiting cav3.2-usp5 interactions.'

Inventor(s) include Patel, Ketulbhai; Derksen, Darren; and Zamponi, Gerald W.

The application for the patent was published on Oct. 10, under issue no. 41/2025.

According to the abstract released by the Intellectual Property India: "The present application relates to various uses of 5-membered cyclo-fused tetrahydroquinoline derivatives of Formula (I) in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions between Cav3.2 T-type calcium channels (Ca...